Clin Oncol | Volume 7, Issue 1 | Research Article | Open Access

Oxaliplatin Anticancer Drug Action in Experimentally Induced Oral Carcinogenesis by Assessed DNA Flow Cytometry

Hussein AM1*, Badawy M2 and Soliman OH3

1Department of Oral and Maxillofacial Pathology, Assiut University, Egypt
2Department of Oral Biology, Assiut University, Egypt
3Department of Oral Medicine, South Valley University, Egypt

*Correspondance to: Ahmed Mohammad Hussein 

Fulltext PDF


Introduction: Oral squamous cell carcinoma is one of the most widespread cancer which totalizes more than 90% of oral malignancies. Therefore, the conception of detaining or preventing the malignant transformation remains a viable target for the future. Oxaliplatin is a third-generation platinum-based chemotherapy cure that has value in the treatment against several forms of
neoplasms. Structurally, it holds a 1,2-diaminocyclohexane carrier ligand which intensifies its antitumor activity. It forms intrastrand links between two adjoining DNA bases, hence disrupting its replication and transcription.
Aim of the Study: The current work was carried out to report the oxaliplatin drug as a chemotherapeutic agent during DMBA-induced squamous cell carcinoma in hamster buccal pouch, utilizing the histopathology and the flow cytometry analysis.
Material and Methods: A total of 60 Syrian hamsters distributed as 2 animals examined for the normal pouch mucosa and 58 hamsters divided into; 6 experiments for Group I, their pouches were painted only with mineral oil. The remaining 52 animals for Group II, in which their pouches were treated by DMBA, mixed in a mineral oil. After 6 weeks, the hamsters separated randomly
into 2 subgroups; Group IIA, were persisted operated in DMBA. Group IIB, were employed to DMBA and injected intraperitoneally with oxaliplatin. The experimental animal’s tissue retained for histopathological evaluation and flow cytometric investigation through the carcinogenesis process.
Results: Oxaliplatin revealed effectiveness and tolerance in turn down the DMBA carcinogenesis procedure in a dosage of 4 mg/kg once weekly. Additionally, the chemotherapeutic results of oxaliplatin detected a significant reduction relation to the DNA aneuploidy and the S-phase fraction throughout the tumorigenic activity.
Conclusion: Oxaliplatin provided a proper strategy as a chemotherapeutic curing for control oral carcinogenesis process with a notable reduction of cancer incidence through reducing the nuclear proliferation activity and induction of cellular apoptosis.


Oral squamous cell carcinoma; Oxaliplatin; Flow cytometry


Hussein AM, Badawy M, Soliman OH. Oxaliplatin Anticancer Drug Action in Experimentally Induced Oral Carcinogenesis by Assessed DNA Flow Cytometry. Clin Oncol. 2022;7:1954..

Subscribe to Our Newsletter